Vorapaxar
Administration
- Type: Antiplatelet
- Dosage Forms: Tab 2.08mg
- Routes of Administration: Oral
- Common Trade Names: Zontivity
Adult Dosing
Thrombotic event prevention
- 2.08 mg PO qd
Pediatric Dosing
Safety/efficacy not established in pediatric patients
Special Populations
Pregnancy Rating
- Caution advised during pregnancy
- Risk of increased maternal bleeding during delivery
Lactation risk
- Consider alternative while breastfeeding
- Possible drug excretion into milk based on drug properties
Renal Dosing
- Adult: No adjustment
- Pediatric: Unavailable
Hepatic Dosing
- Adult:
- Severe Impairment: Avoid use
- Pediatric: Unavailable
Contraindications
- Allergy to class/drug
- Stroke or TIA hx
- Intracranial hemorrhage
- Active bleeding
Adverse Reactions
Serious
- Bleeding, severe
- Intracranial hemorrhage
- GI Bleeding
- Retinopathy
Common
- Bleeding, anemia
- Depression
- Rash
Pharmacology
- Half-life: 8 days w/ active metabolite
- Metabolism: Liver CYP450: 2J2, 3A4 substrate
- Excretion: Feces 58%, urine 25%
Mechanism of Action
- Antagonizes protease-activated receptor-1, inhibiting platelet aggregation induced by thrombin an thrombin receptor agonist peptide